GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medivir AB (LTS:0GP7) » Definitions » Cyclically Adjusted PS Ratio

Medivir AB (LTS:0GP7) Cyclically Adjusted PS Ratio : 0.42 (As of Jun. 10, 2024)


View and export this data going back to . Start your Free Trial

What is Medivir AB Cyclically Adjusted PS Ratio?

As of today (2024-06-10), Medivir AB's current share price is kr2.92669. Medivir AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was kr6.95. Medivir AB's Cyclically Adjusted PS Ratio for today is 0.42.

The historical rank and industry rank for Medivir AB's Cyclically Adjusted PS Ratio or its related term are showing as below:

LTS:0GP7' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.37   Med: 1   Max: 4.77
Current: 0.49

During the past years, Medivir AB's highest Cyclically Adjusted PS Ratio was 4.77. The lowest was 0.37. And the median was 1.00.

LTS:0GP7's Cyclically Adjusted PS Ratio is ranked better than
91.24% of 502 companies
in the Biotechnology industry
Industry Median: 5.43 vs LTS:0GP7: 0.49

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Medivir AB's adjusted revenue per share data for the three months ended in Mar. 2024 was kr0.004. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is kr6.95 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Medivir AB Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Medivir AB's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medivir AB Cyclically Adjusted PS Ratio Chart

Medivir AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.88 0.60 1.15 1.02 0.40

Medivir AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.87 0.77 0.78 0.40 0.42

Competitive Comparison of Medivir AB's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Medivir AB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medivir AB's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medivir AB's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Medivir AB's Cyclically Adjusted PS Ratio falls into.



Medivir AB Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Medivir AB's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=2.92669/6.95
=0.42

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medivir AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Medivir AB's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.004/132.2054*132.2054
=0.004

Current CPI (Mar. 2024) = 132.2054.

Medivir AB Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 12.137 100.432 15.977
201409 13.156 100.161 17.365
201412 8.053 100.225 10.623
201503 4.943 99.950 6.538
201506 5.649 99.995 7.469
201509 2.582 100.228 3.406
201512 -2.255 100.276 -2.973
201603 0.509 100.751 0.668
201606 0.913 101.019 1.195
201609 0.636 101.138 0.831
201612 0.246 102.022 0.319
201703 0.507 102.022 0.657
201706 0.270 102.752 0.347
201709 0.169 103.279 0.216
201712 0.140 103.793 0.178
201803 0.132 103.962 0.168
201806 0.078 104.875 0.098
201809 0.083 105.679 0.104
201812 0.376 105.912 0.469
201903 0.055 105.886 0.069
201906 0.102 106.742 0.126
201909 0.047 107.214 0.058
201912 0.039 107.766 0.048
202003 0.246 106.563 0.305
202006 0.135 107.498 0.166
202009 0.037 107.635 0.045
202012 0.040 108.296 0.049
202103 0.184 108.360 0.224
202106 0.013 108.928 0.016
202109 0.012 110.338 0.014
202112 0.205 112.486 0.241
202203 0.007 114.825 0.008
202206 0.007 118.384 0.008
202209 0.016 122.296 0.017
202212 0.034 126.365 0.036
202303 0.007 127.042 0.007
202306 0.029 129.407 0.030
202309 0.012 130.224 0.012
202312 0.042 131.912 0.042
202403 0.004 132.205 0.004

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Medivir AB  (LTS:0GP7) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Medivir AB Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Medivir AB's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Medivir AB (LTS:0GP7) Business Description

Industry
Traded in Other Exchanges
Address
Lunastigen 5, PO Box 1086, 2nd floor, Huddinge, SWE, 141 22
Medivir AB develops drugs with a focus on cancers where there are medical needs. The company invests in indication areas where available treatment methods are limited or lacking and there are opportunities to offer significant improvements to patients. Medivir focuses on the development of MIV-818, a prodrug that has been designed to provide a targeted anti-tumor effect in the liver while minimizing any side effects. Birinapant, a SMAC mimetic, has been out-licensed for development in combination with IGM antibodies for the treatment of solid tumors.

Medivir AB (LTS:0GP7) Headlines

No Headlines